influenza hemagglutinin vaccine

Influenza hemagglutinin vaccines are a class of immunizations that utilize the hemagglutinin (HA) surface glycoprotein of influenza viruses to elicit a protective immune response. HA is a critical target for vaccination because it mediates viral attachment to host sialic acid receptors and subsequent membrane fusion; antibodies against the HA 'head' or 'stalk' regions can neutralize the virus and prevent infection. These vaccines are produced through various methods, including recombinant DNA technology in insect or mammalian cell lines (e.g., Flublok), or as split-virion/subunit preparations from viruses grown in embryonated chicken eggs or cell cultures. Modern iterations often incorporate novel adjuvants (such as oil-in-water emulsions or TLR agonists) to enhance immunogenicity and provide broader cross-protection against drifted seasonal strains or emerging pandemic threats like H5N1 and H7N9. They are typically administered via intramuscular injection, though intranasal and oral formulations have been investigated to induce mucosal immunity.

Other names

influenza HA vaccinerecombinant influenza hemagglutinin vaccineHA vaccineHAv